Table 4.
Patient biopsy | Best response | t-HER3 | p-HER3 | HER3 ratio (P/T) | t-AKT | p-AKT | AKT ratio (P/T) |
---|---|---|---|---|---|---|---|
1 | PD | −86% ↑ | 81% ↓ | 90% ↓ | 7% ↓ | 84% ↓ | 83% ↓ |
2 | SD | ND | −157% ↑ | ND | −249% ↑ | −84% ↑ | 47% ↓ |
3 | PD | ND | 63% ↓ | ND | ND | ND | ND |
4 | SD | 25% ↓ | ND | ND | −33% ↑ | 0% | 25% ↓ |
5 | SD | 72% ↓ | 82% ↓ | 34% ↓ | 70% ↓ | ND | ND |
Median | 25% | 72% ↓ | 62% ↓ | −13% ↑ | 0% | 47% ↓ |
Percentages represent changes in the post-baseline sample against the baseline value
Positive and negative values represent biomarker inhibition (↓) and stimulation (↑), respectively
HER3 human epidermal growth factor receptor 3, ND not determined, PD progressive disease, p-AKT phosphor-AKT, p-HER3 phospho-HER3, Q2W once every two weeks, QW once weekly, SD stable disease, t-AKT total AKT, t-HER3 total HER3